Abstract:Gene directed enzyme pro-drug therapy (GDEPT) is one of the adjuvant therapeutic regimens for advanced prostate adenocarcinoma, and this research intended to explore how to apply targeting therapy of prostate adenocarcinoma under the mediation of a promoter/enhancer of prostate-specific membrane antigen (PSMA(EP)) as a specific regulatory element. Recombinant adenoviruses (Ad-PSMA(E-P)-enhanced green fluorescent protein [EGFP], Ad-CMV-EGFP, Ad-PSMA(E-P)-CD, and Ad-CMV-CD) were constructed and could express cytosine deaminase (CD) or the EGFP reporter gene driven by a PSMAEP or cytomegalovirus (CMV) promoter. LNCaP, CL-1, MCF-7, and A549 were infected with CD-produced recombinant adenoviruses and treated with pro-drug 5-fluorocytos,ine (5-FC) in vivo and vitro; then, the growth inhibition of the cells and the cell cycle variation were assessed by an [3-(4,5dimethylthazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT) assay and flow cytometry. Growth suppression of the xenograft tumor was also adopted to evaluate the efficiency of the suicide system. Morphologic changes after treatment in vivo were assessed with hematoxylin and eosin staining. In the 4 examined cancer cell lines, PSMA-positive prostate cancer cells LNCap and CL-1 were exclusively sensitive to the Ad-PSMA(E-P)-CD/5-FC system. The S phase of cell cycle arrest was thought to be involved in the cytotoxicity of 5-fluorouracil (5-FU) converted from 5-FC by CD. CL-1 implanted Athymic BALB/c mice showed growth inhibition of tumors when they were treated with the Ad-PSMA(E-P)-CD/5-FC system without systemic conversion toxicity. The PSMA-based, CD-produced adenovirus, deserving further investigation in the future, might be a good candidate and flow cytometry. Growth suppression of the xenograft tumor was also adopted to evaluate the efficiency of the suicide system. Morphologic changes after treatment in vivo were assessed with hematoxylin and eosin staining. In the 4 examined cancer cell lines, PSMA-positive prostate cancer cells LNCap and CL-1 were exclusively sensitive to the Ad-PSMA(E-P)-CD/5-FC system. The S phase of cell cycle arrest was thought to be involved in the cytotoxicity of 5-fluorouracil (5-FU) converted from 5-FC by CD. CL-1 implanted Athymic BALB/c mice showed growth inhibition of tumors when they were treated with the Ad-PSMA(E-P)-CD/5-FC system without systemic conversion toxicity. The PSMA-based, CD-produced adenovirus, deserving further investigation in the future, might be a good candidate for targeting gene therapy of prostate adenocarcinoma.

Construction and expression of replication-deficient recombinant adenoviral vector carrying prostate specific membrane antigen gene

Construction of Human Prostate Specific Membrane Antigen Extracellular Domain Gene Recombinant Adenovirus

Construction and Expression of Secretary Recombinant Adenovis Vectors Carrying Mpsma

Construction and evaluation of a prostate cancer specific oncolytic adenovirus armed with immunogene

Construction and Expression of 4-1BBL Recombinant Adenovirus Vector

The Construction of Recombinant Plasmid with Prostate-specific Membrane Antigen Promoter Controlling Reporter Gene Expression

Construction of prostate-specific expressed recombinant plasmids with high transcriptional activity of prostate-specific membrane antigen (PSMA) promoter/enhancer.

Construction and Evaluation of Prostate Cancer Specific Promoter P(A)PTp

Construction of a recombinant adenovirus co-expressing truncated human prostate-specific membrane antigen and mouse 4-1BBL genes and its effect on dendritic cells.

Construction and Expression of Recombinant Human Prostate-Specific Antigen Expression Vector Ppiczα-Mpsa

Construction and Sequence Analysis of Eukaryotic Expression Vector of Chinese Prostate-Specific Membrane Antigen

Immunological Response of Mice Induced by Recombinant Adenovirus Carrying Rat Prostate-specific Membrane Antigen Gene

Construction of eukaryotic expression vector and package of lentivirus vector encoding prostate cancer antigen 3

Construction of phage-displayed antibody library of Chinese prostate carcinoma patients and screening it with prostate specific membrane antigen

Recombinant adenovirus mediated prostate-specific enzyme pro-drug gene therapy regulated by prostate-specific membrane antigen (PSMA) enhancer/promoter.

Construction and Identification of a Prostatic Androgen-Independent Promoter Mediated ODC and AdoMetDC Antisense RNA-expressing Adenovirus

Prokaryotic expression,identification,primary purification of human prostate specific membrane antigen

DNA vaccine expressing PSMA elicits suppresses tumor cells

Construction and identification of recombinant adenoviral vector-carrying BMP2

Immune Response Against Prostate Cancer Cells Induced by Recombinant Adenovirus Encoding Truncated Prostate Specific Membrane Antigen Gene and 4-1BBL Gene Modified Dendritic Cells in Vitro

Expression of Prostate-Specific Membrane Antigen(psma)after the Transfection of Shrna Lentivirus with PSMA Construction in 293 Cells